Home
Life Sciences

Sector: Life Sciences

Huawei, Intel among big firms selling patents in June-recorded transactions

Two deals could bring NPE risk but others stem from bankruptcies, buying and selling of business units and company product collaborations

Historic moment as UPC hands down two full decisions within 24 hours of each other

The Unified Patent Court has handed patentees a win and a loss in its first on-the-merits rulings

Pharma patent litigation highlights in Southeast Asia in early 2020s

Rouse highlights some of the most important pharma patent decisions issued by Southeast Asian courts in the past four years

Latest content

IP-savvy activist shareholders + declining patent values + tightening patent eligibility = potential trouble for public companies

The PIPCO sector has attracted its share of - sometimes less than sophisticated - investor interest and there are a number of investors that are active around privately-held licensing-based businesses. There are also various kinds of financial model…

26 January 2015

Hammering “trolls” harms US prosperity, says top BASF IP strategist

US legislators have arrived back on Capitol Hill with patent reform again firmly on the agenda. Congressman Bob Goodlatte, chairman of the House of Representatives Judiciary Committee and author of the Innovation Act in the last Congress, has made…

19 January 2015

How patents and licensing underpin the multi-trillion dollar mobile communications economy

A new report has outlined the crucial roles that long-term R&D, a robust IP system and a collaborative approach to technology standards and licensing have played in the development of the mobile sector. The report by the Boston Consulting Group,…

16 January 2015

NPE suits in the US down significantly in 2014 and figures make it clear that SMEs are very much a secondary target

The 2014 Patent Litigation Report published earlier this week by Unified Patents is a treasure trove of statistics. Not surprisingly for a firm whose business model is focused on helping clients defend against “frivolous lawsuits” primarily…

10 January 2015

An IPR warning shot for pharma that could resonate far and wide

Earlier this week US hedge fund investor Kyle Bass got the wires buzzing when he reportedly outlined his plans to wage an inter partes review (IPR) war on big pharma at the USPTO’s Patent Trial and Appeal Board (PTAB). According to Bass,…

09 January 2015

Draft Indian IP strategy aims to kickstart patent market

India’s six-member IPR Think Tank recently made public the first draft of its much-anticipated proposal for a ‘National IPR Policy’ (you can read the document in full here). Earlier this week, IAM’s sister publication World Trademark Review analysed…

09 January 2015

Unlock unlimited access to all IAM content